Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples